Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paula Barnes

Family Medicine Westmont, IL Medical Doctor

NPI 1194068700 CMS profile 3023350

460 Quail Ridge Dr, Westmont, IL 60559

Open in the dashboard

General payments

$182,113

530 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paula Barnes of Westmont, IL is reported in the CMS Open Payments database as having received $182,113 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $77,244 150
2024 General $100,029 234
2023 General $832 41
2022 General $803 42
2021 General $757 40
2020 General $1,419 21
2019 General $1,030 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paula Barnes
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Paula Barnes were reported at $77,244. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Paula Barnes Family Medicine median Middle half National median
2019 $1,030 $150 $41–$543 $163
2020 $1,419 $120 $32–$415 $114
2021 $757 $137 $35–$551 $132
2022 $803 $137 $37–$512 $149
2023 $832 $149 $42–$545 $160
2024 $100,029 $156 $44–$560 $164
2025 $77,244 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Lilly USA, LLC $178,143 342 payments
  2. Novo Nordisk Inc $2,182 109 payments
  3. Currax Pharmaceuticals LLC $681 52 payments
  4. Boston Scientific Corporation $187 1 payment
  5. Endo Pharmaceuticals Inc. $183 11 payments
  6. Abbott Laboratories $157 2 payments
  7. Corcept Therapeutics $141 2 payments
  8. Aimmune Therapeutics, Inc. $134 2 payments
  9. VIVUS, Inc. $118 2 payments
  10. KVK-Tech, Inc. $43 1 payment
  11. Other $144 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $133,875 136 payments
  2. Travel and Lodging $33,356 114 payments
  3. Food and Beverage $7,457 274 payments
  4. Consulting Fee $7,425 6 payments
Products named General payments · program years 2019–2025
  1. ZEPBOUND $134,496 229 payments
  2. MOUNJARO $1,468 5 payments
  3. Wegovy $785 36 payments
  4. CONTRAVE $648 50 payments
  5. Saxenda $591 42 payments
  6. Ozempic $408 22 payments
  7. RYBELSUS $407 22 payments
  8. APOLLO ESG System $187 1 payment
  9. NASCOBAL $183 11 payments
  10. FreeStyle Libre 3 $157 2 payments
  11. Other $645 19 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

188

Median for Family Practice: 1,826

Drug cost

$213,797

Median for Family Practice: $120,094

Branded share of claims

92%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 127 $161,751
Mounjaro Tirzepatide Brand 46 $51,963
Topiramate Generic 15 $84

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 9 billing codes

Paid by Medicare

$25,394

Medicare's payments for the services billed

Medicare patients

92

Average age 69

Services billed

367

71 women, 21 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 64%
Diabetes 29%
Depression 23%
Ischemic heart disease 22%
Chronic kidney disease 20%
Heart failure 14%
COPD 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ZEPBOUND
  • Lilly USA, LLC $74,434
$74,434 — —
MOUNJARO
  • Lilly USA, LLC $1,415
$1,415 46 —
Wegovy
  • Novo Nordisk Inc $336
$336 — —
CONTRAVE
  • Currax Pharmaceuticals LLC $220
$220 — —
Korlym
  • Corcept Therapeutics $141
$141 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record